Latest Financial Health News

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Scalare Partners reported a remarkable 231% revenue increase in Q2 FY26, driven by full integration of recent acquisitions and new ecosystem initiatives. The company also turned operating cashflow positive, signalling strong momentum ahead.

Ampol Limited reports a robust fourth quarter Lytton Refiner Margin of US$15.14 per barrel, underpinning a strong preliminary FY25 earnings update with an expected EBIT of approximately $945 million.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.

Strategic Elements Ltd reports steady progress in its cutting-edge ventures across automation, AI, and material science, supported by a strong cash position and government-backed innovation incentives.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

West African Resources Limited reported a robust cash flow for the December 2025 quarter, ending with a strong cash position of A$584.1 million. The company’s operating activities generated significant cash inflows, offsetting substantial investing and financing outflows.

3D Energi Limited has voluntarily suspended trading of its shares on the ASX as it navigates funding challenges and the future of its VIC/P79 exploration permit. The suspension will last until early February or until further updates are provided.

Multistack International Limited has announced plans to discontinue its current business operations and is working towards disposing of its Australian subsidiary after continued losses and cash burn.

Supply Network Limited has forecast a solid half-year profit of $22.9 million alongside a fully franked interim dividend of 36 cents per share, signalling steady performance in its supply chain operations.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.